| Excerpt | Reference |
|---|
| "Twelve women with congenital adrenal hyperplasia are reported." | ( Lev-Ran, A, 1975) |
| "Late-onset congenital adrenal hyperplasia is a cause of a spectrum of clinical manifestations of postnatal androgen excess." | ( Cordray, JP; Guillerd, X; Merceron, RE; Nys, P; Rainaut, M; Reboul, P, 1992) |
| "Late-onset congenital adrenal hyperplasia is a mild genetic defect in steroidogenesis that presents with hirsutism and menstrual irregularities and responds to specific treatment with dexamethasone sodium phosphate." | ( Baskin, HJ, 1987) |
| "Congenital adrenal hyperplasia is one of a few inherited disorders that can be managed by administering medication to the fetus via oral maternal administration." | ( New, MI; Speiser, PW, 1994) |
| "Congenital adrenal hyperplasia is the most frequent cause of adrenal insufficiency and ambiguous genitalia in newborn children." | ( Bettendorf, M; de Launoit, Y; Gordon, RD; Heinrich, U; Laflamme, N; Luu-The, V; Rhéaume, E; Sanchez, R; Simard, J; van Seters, AP, 1993) |
| "Congenital adrenal hyperplasia is a family of inborn errors of steroidogenesis, each characterized by a specific enzyme deficiency that impairs cortisol production by the adrenal cortex, and can lead to sexual ambiguity in both genetic males and females." | ( New, MI, 1998) |
| "The congenital adrenal hyperplasias are the commonest cause of ambiguity of the external genitalia at birth, although sexual differentiation in these disorders is strictly normal." | ( Hughes, IA, 1998) |
| "Congenital adrenal hyperplasia is diagnosed by demonstration of excess cortisol precursors in the serum during an adrenal corticotropic hormone challenge." | ( Deaton, MA; Glorioso, JE; McLean, DB, 1999) |
| "Congenital adrenal hyperplasia is one of the most frequently inherited diseases." | ( Bernhardt, R; Dao, NT; Hampf, M; Hoan, NT, 2001) |
| "Late-onset congenital adrenal hyperplasia is a relatively uncommon cause of hirsutism in the Kashmir Valley." | ( Bashir, MI; Laway, BA; Masoodi, SR; Salahuddin, M; Wani, AI; Zargar, AH, 2002) |
| "Congenital adrenal hyperplasia is a group of autosomal recessive inherited disorders of steroidogenesis." | ( Grischuk, Y; Grötzinger, J; Holterhus, PM; Krone, N; Müller, M; Riepe, FG; Sippell, WG; Volk, RE, 2006) |
| "Congenital adrenal hyperplasia is a general term applied to a group of several inherited enzymatic defects of cortisol biosynthesis." | ( Herman, ZS; Krysiak, R; Okopień, B, 2006) |
| "Congenital adrenal hyperplasia is a group of inherited disorders caused by an enzyme deficiency in steroid biosynthesis." | ( New, MI; Nimkarn, S, 2007) |
| "Classical forms of congenital adrenal hyperplasia are caused by a severe deficiency of 21-hydroxylase, an enzyme involved in steroid biosynthesis, which triggers excessive androgen production before birth." | ( New, MI; Nimkarn, S, 2007) |
| "Congenital adrenal hyperplasia is a group of autosomal recessive disorders resulting from the deficiency of one of the five enzymes required for the synthesis of cortisol in the adrenal cortex." | ( Biason-Lauber, A; Torresani, T, 2007) |
| "Congenital adrenal hyperplasia is a group of disorders caused by defects in the adrenal steroidogenic pathways." | ( Dauber, A; Kellogg, M; Majzoub, JA, 2010) |
| "Congenital adrenal hyperplasia is an autosomal recessive disorder; 21-hydroxylase deficiency (21OHD) is the most common form of the disease." | ( Lekarev, O; New, MI, 2011) |
| "Congenital adrenal hyperplasia is generally associated with oligo-amenorrhea, and its presentation with polymenorrhagia is rare." | ( Hayat, M; Rizwan, A, 2015) |
| "Congenital adrenal hyperplasia is a genetic endocrinologic disorder." | ( Dey, AC; Dey, SK; Khan, KA; Mannan, MA; Nahar, N; Shahidullah, M, 2016) |
| "Congenital adrenal hyperplasia is an autossomic recessive condition." | ( Ferraz Liz, C; Rocha, A, 2021) |
| "Congenital Adrenal Hyperplasia is a group of autosomal recessive disorders due to deficiencies of enzymes involved in steroidogenesis." | ( Adhikari, U; Khanal, D; Mandal, D; Phuyal, R, 2020) |
| "Congenital adrenal hyperplasia is a group of autosomal recessive disorders leading to multiple complex hormonal imbalances caused by various enzyme deficiencies in the adrenal steroidogenic pathway." | ( Auer, MK; Lajic, S; Nordenström, A; Reisch, N, 2023) |
| "Congenital adrenal hyperplasia is a group of autosomal recessive disorders leading to multiple complex hormonal imbalances caused by various enzyme deficiencies in the adrenal steroidogenic pathway." | ( Auer, MK; Lajic, S; Nordenström, A; Reisch, N, 2023) |
| "Congenital Adrenal Hyperplasia is a group of autosomal recessive diseases due to deficiencies of enzymes involved in steroidogenesis." | ( Adhikari, A; Adhikari, N; Chapagain, N; Mandal, D; Paudel, S, 2023) |
| Excerpt | Reference |
|---|
| "Two male children with congenital adrenal hyperplasia due to a 11-beta-hydroxylase defect are described, in whom gynaecomastia developed before institution of therapy, or when the treatment was inadequate." | ( Kaufman, H; Laron, Z; Levin, S; Pertzelan, A; Zadik, Z, 1979) |
| "Therapy of congenital adrenal hyperplasia tranditionally is monitored by the amount of urinary 17-KS." | ( Bryan, GT; Cavallo, A; Corn, C; Meyer, WJ, 1979) |
| "Five cases of congenital adrenal hyperplasia due to C21-hydroxylase defect were treated with a combination of aminoglutethimide and prednisolone." | ( Hamilton, W, 1976) |
| "Thirteen of these were cases of untreated congenital adrenal hyperplasia (CAH) and 2 were cases of tumoral (one sertoli leydig cell tumor of the ovary and one adrenal adenoma) hyperandrogenism." | ( Ahuja, MM; Ammini, AC; Buckshee, K; Gupta, R; Karmarkar, MG; Sunderaraman, PG, 1992) |
| "Prenatal treatment of virilizing congenital adrenal hyperplasia in female fetuses via maternal dexamethasone (Dex) therapy (1-1." | ( Clark, AT; Dolan, LM; Freeman, LC; Immken, L; Mueller, OT; Pang, S; Shulman, DI; Stiff, D, 1992) |
| "prenatal Dex treatment of virilizing congenital adrenal hyperplasia at a dose of 1-1." | ( Clark, AT; Dolan, LM; Freeman, LC; Immken, L; Mueller, OT; Pang, S; Shulman, DI; Stiff, D, 1992) |
| "A couple whose son had congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency sought prenatal diagnosis and treatment in their next pregnancy." | ( Antonis, P; Haan, EA; Norman, R; Penfold, JL; Richards, RI; Rollond, AK; Serjeantson, SW, 1992) |
| "A 14-year-old girl with congenital adrenal hyperplasia showed rapid conversion from undertreatment to overtreatment when primidone, used to treat coexistent epilepsy, was withdrawn while on a constant steroid dose." | ( Hughes, IA; Young, MC, 1991) |
| "Ten patients with congenital adrenal hyperplasia (three males, seven females; aged 12-29 years) had their usual glucocorticoid treatment changed to dexamethasone in three crossover dosage regimens." | ( Hughes, IA; Young, MC, 1990) |
| "We have compared three treatments of congenital adrenal hyperplasia (CAH) for their effect on physical development." | ( Itoh, N; Kumamoto, Y; Maruta, H; Mikuma, N; Nanbu, A; Tachiki, H; Takagi, Y; Tsunekawa, T, 1989) |
| "A multicentric study of prenatal treatment of congenital adrenal hyperplasia (CAH) resulting from 21-hydroxylase deficiency in 43 pregnancies at risk for CAH is presented." | ( Bétuel, H; David, M; Forest, MG, 1989) |
| "In 7 patients treated for classical congenital adrenal hyperplasia associated with 21-hydroxylase deficiency, basal values varied between 9." | ( Brerault, JL; Fiet, J; Galons, H; Gourmelen, M; Gueux, B; Julien, R; Pham-Huu-Trung, MT; Vexiau, P; Villette, JM, 1985) |
| "Late-onset congenital adrenal hyperplasia is a mild genetic defect in steroidogenesis that presents with hirsutism and menstrual irregularities and responds to specific treatment with dexamethasone sodium phosphate." | ( Baskin, HJ, 1987) |
| "These observations suggest that treatment of congenital adrenal hyperplasia with a once-a-day hydrocortisone dose schedule may be as effective as conventional multiple-dose schedules." | ( Chrousos, GP; Cutler, GB; Loriaux, DL; Winterer, J, 1985) |
| "A case report of stimulated congenital adrenal hyperplasia in a newborn male following a medroxyprogesterone-treated pregnancy is presented." | ( Kelley, VC; Limbeck, GA; Ruvalcaba, RH, 1969) |
| "A girl with congenital adrenal hyperplasia due to 21-hydroxylase deficiency could not be controlled by conventional treatment, and was adrenalectomized at age 8." | ( Atares, M; Kempken, B; Knorr-Muerset, G; Manella, B; Prader, A; Zachmann, M, 1984) |
| "In salt-losing congenital adrenal hyperplasia (CAH), treatment with a mineralocorticoid in doses that normalized plasma renin activity (PRA) induced a marked increase in linear growth." | ( Gunzcler, P; Kuhnle, U; Levine, LS; New, MI; Pareira, JA; Rösler, A, 1983) |
| "The treatment of congenital adrenal hyperplasia (hypertensive forms) is based, as in the other forms of congenital adrenal hyperplasia, on corticosteroid therapy." | ( de Gennes, JL; Heshmati, HM; Jambart, S; Turpin, G, 1983) |
| "In 6 patients with salt-losing congenital adrenal hyperplasia due to 21-hydroxylase deficiency, the renin activity was also elevated and normalized after corticoid treatment." | ( Büchner, M; Dörner, G; Garten, CD; Hubl, W; Schmidt, PK, 1981) |
| "The mean age at menarche in 6 girls on treatment for congenital adrenal hyperplasia from infancy was 13." | ( Hughes, IA; Read, GF, 1982) |
| "In a female with untreated congenital adrenal hyperplasia and an adult bone age, signs of puberty appeared very rapidly once appropriate treatment had begun." | ( Jocham, A; Kuhnle, U; Schwarz, HP, 1995) |
| "Since 1986, prenatal diagnosis and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD) have been carried out in 239 pregnancies." | ( Cheng, KC; Mercado, AB; New, MI; Wei, JQ; Wilson, RC, 1995) |
| "Impaired final height in congenital adrenal hyperplasia is more likely to be due to over treatment, particularly in infancy when lower doses of corticosteroids may improve height prognosis." | ( Abbott, GD; Espiner, EA; Rasat, R, 1995) |
| "The subjects were 75 children with congenital adrenal hyperplasia, aged 1-18 years, treated with glucocorticoids and mineralocorticoids in substitution doses from birth." | ( Lisá, L; Neradilová, M; Soutorová, M; Tomásová, N; Zimák, J, 1995) |
| "Eight children with congenital adrenal hyperplasia and late initiation of corticosteroid treatment are included in the present study." | ( Dacou-Voutetakis, C; Karidis, N, 1993) |
| "Prenatal diagnosis of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency by amniotic fluid (AF) steroid analysis is not possible in those cases in which prenatal dexamethasone (DEX) therapy is initiated to prevent virilization of female CAH fetuses because AF steroid levels are suppressed if DEX therapy is continued beyond amniocentesis (AC)." | ( Dörr, HG; Sippell, WG, 1993) |
| "A female with congenital adrenal hyperplasia (21-hydroxylase deficiency) received prenatal dexamethasone treatment." | ( Couper, JJ; Hutson, JM; Warne, GL, 1993) |
| "We report two cases of congenital adrenal hyperplasia (CAH) in which administration of chlormadinone acetate (CMA), a substituted progestational agent for prostatic disease, suppressed ACTH hypersecretion and lowered plasma testosterone levels." | ( Goto, S; Kageyama, Y; Kitahara, S; Oshima, H; Tsujii, T; Tsukamoto, T, 1995) |
| "The patient was diagnosed with congenital adrenal hyperplasia (CAH) and received hormone therapy." | ( Herold, DA; Seely, BL; Summers, RH, 1996) |
| "Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both." | ( Barnes, KM; Cutler, GB; Hill, S; Jones, JV; Laue, L; Merke, DP, 1996) |
| "Monitoring therapy for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase is difficult, although plasma determinations of 17 alpha-hydroxyprogesterone (17OHP), delta 4-androstenedione (delta 4A) and testosterone are helpful." | ( Catzeflis, C; Cicotti, I; Lopes, LA; Rey, C; Sizonenko, PC, 1997) |
| "It is known that certain patients with congenital adrenal hyperplasia require very high substitution doses of cortisone acetate, and a few patients do not respond to this treatment at all." | ( Axelson, M; Marcus, C; Nordenström, A; Ritzén, EM; Wedell, A, 1999) |
| "Treatment outcome in congenital adrenal hyperplasia is often sub-optimal due to hyperandrogenism, treatment-induced hypercortisolism, or both." | ( Cutler, GB; Fields, J; Hill, S; Jones, JV; Keil, MF; Merke, DP, 2000) |
| "In 22 patients with congenital adrenal hyperplasia (CAH), the effect of treatment on growth was evaluated retrospectively." | ( Ercan, O; Hatemi, S; Kutlu, E; Turan, N, 2000) |
| "The early diagnosis and therapy of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency can prevent adrenal crises and erroneous gender assignment in affected newborns." | ( Azócar, M; Cattani, A; Foradori, A; Poggi, H; Reyes, ML; Romeo, E; Soto, J; Valdivia, L, 2000) |
| "Pediatric endocrinologists initially treat congenital adrenal hyperplasia with either cortisone acetate (CA) or hydrocortisone (HC)." | ( Fujitaka, M; Jinno, K; Kihara, M; Nomura, S; Sakura, N; Ueda, K, 2001) |
| "Patients with congenital adrenal hyperplasia attributable to 21-hydroxylase deficiency are treated with glucocorticoids." | ( Hermus, AR; Otten, BJ; Oyen, WJ; Stikkelbroeck, NM; van der Wilt, GJ, 2003) |
| "Treatment of congenital adrenal hyperplasia (CAH) requires glucocorticoid replacement (with or without additional mineralocorticoid) at supra-physiological doses to normalize the pituitary adrenocortical axis." | ( Brown, JJ; de Silva, KS; Jones, CL; Kanumakala, S; Warne, GL, 2004) |
| "In foetuses at risk of virilising congenital adrenal hyperplasia (CAH), prenatal treatment can be offered by administration of dexamethasone (DEX) via the mother, in order to suppress foetal adrenal androgen oversecretion and prevent genital malformations." | ( Lajic, S; Nordenström, A; Ritzén, EM; Wedell, A, 2004) |
| "The treatment of congenital adrenal hyperplasia (CAH) before birth was instituted 20 years ago in an attempt to prevent virilization of the external genitalia in affected girls." | ( Hughes, I, 2006) |
| "The primary treatment for patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is glucocorticoid replacement therapy, which at supraphysiologic levels can result in diminished bone accrual and lead to osteopenia and osteoporosis." | ( Lin-Su, K; New, MI, 2007) |
| "Clinical management of patients with congenital adrenal hyperplasia (CAH) involves treating hormonal deficiencies, addressing issues related to genital ambiguity, avoiding morbidities and communicating with the family about risk of CAH in other members." | ( Speiser, PW, 2007) |
| "We investigated the effects of type of congenital adrenal hyperplasia (CAH), treatment, endocrinological, surgical, and socio-demographic factors as well as patients' body perception on the gender-typed play and behavioral and emotional problems in female children with CAH." | ( Aycan, Z; Cetinkaya, E; Kibar, E; Oner, O; Soy, D; Tiryaki, T, 2009) |
| "Existing glucocorticoid treatment for congenital adrenal hyperplasia (CAH) is suboptimal and nonphysiological." | ( Arlt, W; Calis, KA; Kim, MS; Merke, DP; Nieman, LK; Ravindran, S; Ross, RJ; Sinaii, N; Vanryzin, C; Verma, S, 2010) |
| "Patients with congenital adrenal hyperplasia (CAH) are chronically treated with supraphysiological doses of glucocorticoids, which are known to induce insulin resistance." | ( Hermus, AR; Kroese, JM; Mooij, CF; Tack, CJ; van der Graaf, M, 2009) |
| "Prenatal treatment of congenital adrenal hyperplasia (CAH) with dexamethasone (DEX) has been in use since the mid- 1980s." | ( Hirvikoski, T; Lajic, S; Nordenström, A, 2011) |
| "Doses of glucocorticoids used when treating congenital adrenal hyperplasia (CAH) are larger than physiological secretion of hydrocortisone in healthy people." | ( Giżewska, M; Horodnicka-Józwa, A; Kotkowiak, L; Krupa, B; Krzywińska-Zdeb, E; Petriczko, E; Romanowska, H; Safranow, K; Walczak, M, 2012) |
| "We describe a case of non-classical congenital adrenal hyperplasia (NCCAH) due to 21-hydroxylase deficiency in a 30-year-old Japanese woman who achieved pregnancy after treatment of primary amenorrhea." | ( Kanasaki, H; Miyazaki, K; Oride, A; Purwana, IN, 2013) |
| "Adults with congenital adrenal hyperplasia (CAH) are treated with a wide variety of glucocorticoid treatment regimens." | ( Arlt, W; Conway, GS; Han, TS; Krone, N; Rees, DA; Ross, RJ; Stimson, RH; Walker, BR; Willis, DS, 2013) |
| "The patient with non-classical congenital adrenal hyperplasia was treated with hydrocortisone; in the patient with an adrenal adenoma - a rare but severe condition - the adenoma was resected." | ( Backes, M; Kamp, GA; Zwaveling-Soonawala, N, 2012) |
| "Prenatal treatment of congenital adrenal hyperplasia by administering dexamethasone to a woman presumed to be carrying an at-risk fetus has been described as safe and effective in several reports." | ( Miller, WL; Witchel, SF, 2013) |
| "We report 2 patients with congenital adrenal hyperplasia (CAH) due to 21-OHD who were treated prenatally with dexamethasone, suffered from an acute encephalopathy and showed focal and multifocal cortical and subcortical diffusion restrictions in early MRI and signs of permanent alterations in the follow-up neuroimaging studies." | ( Flück, CE; Grunt, S; Mullis, PE; Schöning, M; Steinlin, M; Weisstanner, C, 2013) |
| "Classical congenital adrenal hyperplasia (CAH), a genetic disorder characterized by 21-hydroxylase deficiency, impairs male fertility, if insufficiently treated." | ( Kliesch, S; Mallidis, C; Nieschlag, E; Rohayem, J; Tüttelmann, F; Zitzmann, M, 2014) |
| "The treatment of congenital adrenal hyperplasia requires administration of glucocorticoid and mineralocorticoid to replace the deficit resulting from the enzymatic block." | ( Hindmarsh, PC, 2014) |
| "Treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency can be monitored by salivary androstenedione (A-dione) and 17α-hydroxyprogesterone (17OHP) levels." | ( Claahsen-van der Grinten, HL; de Groot, MJ; Otten, BJ; Pijnenburg-Kleizen, KJ; Stikkelbroeck, NM; Sweep, FC; Thomas, CM, 2015) |
| "Treatment of congenital adrenal hyperplasia (CAH) is suboptimal." | ( Arlt, W; Daley, LA; Digweed, D; Eckland, DJ; Kumar, P; Mallappa, A; Merke, DP; Nieman, LK; Ross, RJ; Sinaii, N; Van Ryzin, C; Whitaker, MJ, 2015) |
| "Prenatal treatment of congenital adrenal hyperplasia by administering dexamethasone to a woman presumed to be carrying an at-risk fetus remains a controversial experimental treatment." | ( Miller, WL, 2015) |
| "The treatment goal in congenital adrenal hyperplasia (CAH) is to replace glucocorticoids while avoiding androgen excess and iatrogenic Cushing's syndrome." | ( Backlund, PS; Crutchfield, CA; Debono, M; Gounden, V; Harrison, RF; Mallappa, A; Merke, DP; Nella, AA; Ross, RJ; Soldin, SJ, 2015) |
| "Glucocorticoid replacement therapy in congenital adrenal hyperplasia (CAH) is challenging, especially in children, because both over- and under-dosing may have profound and long-lasting adverse effects." | ( de Rijke, YB; Koper, JW; Noppe, G; van den Akker, EL; van Rossum, EF, 2016) |
| "Prenatal treatment of congenital adrenal hyperplasia (CAH) has long involved prenatal treatment with dexamethasone, administered to the pregnant woman to prevent genital masculinization of an affected female fetus." | ( Rechitsky, S; Simpson, JL, 2017) |
| "The aim of treatment in congenital adrenal hyperplasia is to suppress excess adrenal androgens while achieving physiological glucocorticoid replacement." | ( Andrew, R; Elfick, AP; Homer, NZ; Livingstone, DE; Mackenzie, SD; Mole, DJ; Morgan, RA; Mouras, R; Nixon, M; Reynolds, RM; Stimson, RH; Taylor, AI; Walker, BR, 2016) |
| "Patients with congenital adrenal hyperplasia (CAH) are at risk of vascular and metabolic complications due to steroid therapy and increased adrenal androgens exposure." | ( Bik-Multanowski, M; Janeczko, M; Janus, D; Starzyk, JB; Tyrawa, K; Wojcik, M, 2017) |
| "Patients with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) require lifelong treatment with glucocorticoids." | ( Barillas, JE; Eichner, D; Speiser, PW; Van Wagoner, R, 2018) |
| "Prenatal dexamethasone (DEX) treatment in congenital adrenal hyperplasia (CAH) is effective in reducing virilization in affected girls, but potential long-term adverse effects are largely unknown." | ( Gezelius, A; Hirvikoski, T; Karlsson, L; Lajic, S; Messina, V; Nordenström, A; Sandberg, MT; Wallensteen, L, 2018) |
| "Prenatal treatment of congenital adrenal hyperplasia with dexamethasone (DEX) has been in use since the mid-1980s and has proven effective at reducing virilization of external genitalia in affected girls." | ( Karlsson, L; Lajic, S; Nordenström, A, 2018) |
| "A probable diagnosis of congenital adrenal hyperplasia (CAH) with salt-wasting crisis was made and treatment was commenced." | ( Canlas, JF; Ponmani, C, 2019) |
| "Background In congenital adrenal hyperplasia (CAH), achieving the balance between overtreatment and undertreatment remains challenging." | ( Claahsen-van der Grinten, HL; Otten, BJ; Pijnenburg-Kleizen, KJ; Roeleveld, N; Thomas, CMG, 2019) |
| "Patients with classic congenital adrenal hyperplasia (CAH) are treated postnatally with lifelong glucocorticoid (GC) replacement therapy." | ( Hirvikoski, T; Karlsson, L; Lajic, S; Messina, V; Nordenström, A, 2020) |
| "Patients with congenital adrenal hyperplasia (CAH) require lifelong replacement therapy with glucocorticoids." | ( Hartung, N; Hindmarsh, P; Huisinga, W; Kloft, C; Melin, J; Michelet, R; Parra-Guillen, ZP; Truong, T, 2020) |
| "Treatment of congenital adrenal hyperplasia (CAH) requires lifelong replacement of glucocorticoids with regular follow up to manage associated morbidities." | ( Batra, P; Dabas, A; Gupta, N; Jain, V; Kabra, M; Kapoor, S; Kumar, R; Seth, A; Sharma, R; Singh, P; Vats, P; Yadav, S, 2020) |
| "Patients with classic congenital adrenal hyperplasia (CAH) are treated postnatally with life-long glucocorticoid (GC) replacement therapy." | ( Balsamo, A; Hirvikoski, T; Karlsson, L; Lajic, S; Messina, V; Nordenström, A; Ortolano, R; Vissani, S; Wallensteen, L, 2020) |
| "Treatment of children with classic congenital adrenal hyperplasia (CAH) is a difficult balance between hypercortisolism and hyperandrogenism." | ( Hartmann, MF; Kamrath, C; Pons-Kühnemann, J; Wudy, SA, 2020) |
| "Thirty-four patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency on regular glucocorticoid treatment for ≥3 years and 31 healthy subjects were included in the study." | ( Abacı, A; Acar, S; Böber, E; Can, Ş; Çatlı, G; Demir, K; Dündar, B; Egeli, T; Güleryüz, H; Öztürk, T; Tuhan, H, 2021) |
| "Standard glucocorticoid therapy in congenital adrenal hyperplasia (CAH) regularly fails to control androgen excess, causing glucocorticoid overexposure and poor health outcomes." | ( Arlt, W; Brac de la Perriere, A; Juul, A; Lindén Hirschberg, A; Mallappa, A; Maltby, K; Merke, DP; Newell-Price, J; Perry, CG; Porter, J; Prete, A; Rees, DA; Reisch, N; Ross, RJ; Stikkelbroeck, N; Touraine, P; Treasure, FP, 2021) |
| "Optimal treatment of pediatric congenital adrenal hyperplasia (CAH) remains a challenge and requires evaluation of all biochemical and clinical markers." | ( Almstrup, K; Johannsen, TH; Juul, A; Ljubicic, ML; Madsen, A, 2021) |
| "Due to classic congenital adrenal hyperplasia, the patient received substitution therapy with hydrocortisone for decades." | ( Adelmeyer, J; Goebel, JN; Kann, PH, 2021) |
| "The standard treatment for congenital adrenal hyperplasia (CAH) in children is still hydrocortisone." | ( Falhammar, H; Lajic, S; Nordenström, A, 2023) |
| "Treatment of congenital adrenal hyperplasia (CAH) patients with glucocorticoids is often challenging since there is a delicate balance between over- and undertreatment." | ( Adriaansen, BPH; Bock, C; Brandt, A; Claahsen-van der Grinten, HL; Kamphuis, JS; Lentjes, EGWM; Olthaar, AJ; Schröder, MAM; Span, PN; Stikkelbroeck, NMML; Sweep, FCGJ; van Herwaarden, AE, 2022) |
| "Glucocorticoid therapy in children with congenital adrenal hyperplasia (CAH) must be finely balanced between optimizing adrenal control and minimizing side effects." | ( Apsan, J; Elnaas, H; Lekarev, O; Lin-Su, K; Thomas, C, 2022) |
| "Although the basic treatment of congenital adrenal hyperplasia (CAH) is well established, there are active clinical research projects to more closely mimic the normal diurnal rhythm of cortisol secretion and to reduce total glucocorticoid doses to minimize adverse metabolic effects." | ( White, PC, 2022) |
| "Treatment for congenital adrenal hyperplasia (CAH) was introduced in the 1950s following the discovery of the structure and function of adrenocortical hormones." | ( Mallappa, A; Merke, DP, 2022) |
| "Children with congenital adrenal hyperplasia (CAH) are treated with glucocorticoids." | ( Abawi, O; Binou, M; Charmandari, E; Flück, CE; Paltoglou, G; Raftopoulou, C; Sommer, G; van den Akker, ELT, 2023) |
| "Treatment of children with congenital adrenal hyperplasia (CAH) with corticosteroids (CS) may increase the risk for developing different components of metabolic syndrome (MetS)." | ( Abdel Meguid, SE; Abougabal, AMS; Ahmed, S; De Sanctis, V; Hamed, N; Hassan, M; Ramadan, MAEF; Soliman, AT, 2022) |
| "Most children with non-classic congenital adrenal hyperplasia (NC-CAH) due to 21-hydroxylase deficiency are asymptomatic and do not require cortisol replacement therapy unless they develop symptoms of hyperandrogenemia." | ( Jaber, M; Liu, SC; Mercado Munoz, Y; Sarafoglou, K; Suresh, M, 2023) |
| "If not diagnosed and treated adequately, Congenital Adrenal Hyperplasia can lead to an acute adrenal crisis with hemodynamic collapse." | ( Adhikari, A; Adhikari, N; Chapagain, N; Mandal, D; Paudel, S, 2023) |
| "Patients with congenital adrenal hyperplasia (CAH) require lifelong therapy with glucocorticoids to suppress androgen excess and substitute for deficient cortisol." | ( Bechtold-Dalla Pozza, S; Debor, B; Dubinski, I; Nowotny, HF; Reisch, N; Schmidt, H; Tschaidse, L, 2023) |
| "Treatment of children with classical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is challenging." | ( Binder, G; Bonfig, W; Dörr, HG; Dübbers, A; Eckert, AJ; Holl, RW; Hoyer-Kuhn, H; Riedl, S; Woelfle, J, 2023) |